-
Second-Line Treatment of Pancreatic Adenocarcinoma: Shedding Light on New Opportunities and Key Talking Points from Clinical Trials
18 Apr 2024 07:34 GMT
… ;II randomized control trial of neoadjuvant chemoradiation with … care treatments for other malignancies. Furthermore, personalized vaccines are … trials that has promising preclinical data. The drug … are still not FDA-approved. **Olaparib is FDA approved as …
-
Ultimovacs downsizes to funnel funds to cancer vaccine programme
17 Apr 2024 17:42 GMT
… trials. The Phase II FOCUS trial (NCT05075122) evaluates the combination treatment of UV1 vaccine … Infinzi (duvalumab) and Lynparza (olaparib), a poly-ADP ribose polymerase … the treatment of head and neck cancers and ISA Pharmaceuticals’ cancer vaccine, …
-
TOPAZ─1 phase III trial shows AstraZeneca's Imfinzi plus chemotherapy doubled OS rate at three years for patients with advanced biliary tract cancer
17 Apr 2024 03:44 GMT
… for the treatment of GI cancers across several medicines and a … and Daiichi Sankyo.
Lynparza (olaparib), a first-in-class PARP … first-in-class antibody drug conjugate licensed from KYM … evaluated in an Investigator Initiated Trial (IIT) in collaboration with …
-
IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial
16 Apr 2024 11:18 GMT
… University College of Medicine, and principal investigator in the trial, said: “The … , including Stevens-Johnson Syndrome (SJS), drug rash with eosinophilia and systemic … for the treatment of BRCA-mutated metastatic pancreatic cancer. Olaparib is developed …
-
CDSCO Panel grants AstraZeneca's proposal for withdrawing specific Indications of Olaparib Tablets
11 Apr 2024 17:20 GMT
… Clinical evidence presented by drug major AstraZeneca, the … functional under the Central Drug Standard Control Organisation (CDSCO … medical or surgical treatments to lower testosterone levels.
Olaparib … drug Olaparib 100mg and 150mg tablets in the treatment …
-
The Role of Oncology Pharmacists Is Evolving in Early-Stage Breast Cancer Treatment Optimization
11 Apr 2024 16:18 GMT
… guidelines yet or received an FDA approval, but really could … , and also the use of olaparib [Lynparza; AstraZeneca and Merck], … the way that the clinical trials were done—and they differ … the treatment can be very complicated for patients. They may have drugs …
-
Blacksmith Medicines To Highlight Preclinical Oncology Data Demonstrating a Potent and Selective FEN1 Inhibitor Has Synergy with Multiple DDR Drug Classes at AACR Annual Meeting 2024
11 Apr 2024 01:16 GMT
… FEN1 inhibition. Treatment of BRCA2-deficient … drug classes that included inhibitors of USP1 (KSQ-4279), PARP (Olaparib … medicines.
About Blacksmith Medicines
At Blacksmith Medicines, … drug discovery collaborations with Basilea Pharmaceutica International …
-
Therapy for Hormone Receptor-Positive, Human Epidermal Growth Receptor 2-Negative Metastatic Breast Cancer Following Treatment Progression via CDK4/6 Inhibitors: A Literature Review
10 Apr 2024 07:09 GMT
… by the Food and Drug Administration (FDA) due to their … alpelisib. Phase IB trials have shown that treatment with combination of … the 2022 European Society for Medical Oncology (ESMO) annual meeting … evaluated the activity of olaparib in 54 mBC patients …
-
Tolerability of Olaparib Combined with Abiraterone in Patients with Metastatic Castration-resistant Prostate Cancer: Further Results from the Phase 3 PROpel Trial.
09 Apr 2024 10:35 GMT
… -blind, placebo-controlled trial was conducted at 126 … no prior systemic mCRPC treatment.
Olaparib (300 mg bid) … medical practice. Overall, 13.8% versus 7.8% of patients discontinued treatment … with olaparib plus abiraterone …
-
Australians Benefit From Cheaper Medicines On PBS
08 Apr 2024 04:05 GMT
… have access to cheaper medicines under the Pharmaceutical Benefits Scheme (PBS).
Australians … $4,000 per year of treatment with inclisiran.
Empagliflozin (Jardiance®) will … ’s recent expanded listing of olaparib (Lynparza®) from January 2024 for …